KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Research & Development (2016 - 2025)

Historic Research & Development for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $3.5 billion.

  • Eli Lilly's Research & Development rose 2675.83% to $3.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 billion, marking a year-over-year increase of 1925.02%. This contributed to the annual value of $11.0 billion for FY2024, which is 1800.85% up from last year.
  • Eli Lilly's Research & Development amounted to $3.5 billion in Q3 2025, which was up 2675.83% from $3.3 billion recorded in Q2 2025.
  • Over the past 5 years, Eli Lilly's Research & Development peaked at $3.5 billion during Q3 2025, and registered a low of $1.6 billion during Q1 2022.
  • Its 5-year average for Research & Development is $2.3 billion, with a median of $2.4 billion in 2023.
  • Its Research & Development has fluctuated over the past 5 years, first crashed by 370.79% in 2022, then skyrocketed by 3362.36% in 2023.
  • Eli Lilly's Research & Development (Quarter) stood at $1.9 billion in 2021, then rose by 5.14% to $2.0 billion in 2022, then increased by 28.4% to $2.6 billion in 2023, then rose by 17.94% to $3.0 billion in 2024, then increased by 14.66% to $3.5 billion in 2025.
  • Its Research & Development was $3.5 billion in Q3 2025, compared to $3.3 billion in Q2 2025 and $2.7 billion in Q1 2025.